perfosfamide
Trade name: Pergamid
Small moleculeexperimental
Perfosfamide, or 4-hydroperoxycyclophosphamide was an experimental drug candidate for blood cancers that was rejected by the FDA in 1993 and never reached the market. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 1993 (NCT00002552)
Timeline
1990s
- Jan 1, 1993
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
O=P1(N(CCCl)CCCl)NC(OO)CCO1- Mol. weight
- 293.09 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPerfosfamide ↗
- ChEMBLCHEMBL61511 ↗
Also known as
- 4-hc
- 4-hc
- 4-hydroperoxycyclophosphamide
- 4-hydroperoxycyclophosphamide
- 4-hydroperoxycyclophosphamide
- hydroperoxycyclofosfamide
- nsc 181815
- nsc-181815
- perfosfamide
- perfosfamide
- perfosfamide
- perfosfamide
- perfosfamide
- perfosfamide
- perfosfamide
- perfosfamide
- pergamid
- pergamid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002634 | Phase 2 | Feb 1, 1995 | Cornell University |
| NCT00002552 | Phase 2 | Oct 1, 1993 | National Cancer Institute (NCI), Wayne State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1995 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1993 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 1993 |
3 organizations
Page 1 / 1